Compare HAFN & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HAFN | ACAD |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | Singapore | United States |
| Employees | 4876 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.3B |
| IPO Year | N/A | 2000 |
| Metric | HAFN | ACAD |
|---|---|---|
| Price | $7.66 | $25.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 22 |
| Target Price | N/A | ★ $30.55 |
| AVG Volume (30 Days) | 1.2M | ★ 1.3M |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.21% | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $726,437,000.00 |
| Revenue This Year | N/A | $18.80 |
| Revenue Next Year | N/A | $11.70 |
| P/E Ratio | ★ $11.39 | $1,327.00 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $5.17 | $19.69 |
| 52 Week High | $9.54 | $28.35 |
| Indicator | HAFN | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 56.17 | 54.10 |
| Support Level | $7.16 | $25.00 |
| Resistance Level | $7.73 | $27.79 |
| Average True Range (ATR) | 0.16 | 0.75 |
| MACD | 0.05 | -0.08 |
| Stochastic Oscillator | 80.18 | 52.73 |
Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk. Company manages it's business through the following reporting segments: LR2 tankers, LR1 tankers, MR tankers, Handy tankers.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.